Impact of universal varicella vaccination in Germany: An epidemiological and economic analysis;Effektivität einer universellen varizellen-schutzimpfung in Deutschland: Eine epidemiologische und gesundheitsökonomische analyse

Klinische Padiatrie

Volumn 218, Issue 4, 2006, Pages 203-212

  Knuf, Markus ^a   Neiss A ^b   Wutzler, P ^c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Benefit cost ratio; Cost effectiveness; Effectiveness; Vaccination; Varicella

Indexed keywords

CHICKENPOX VACCINE;

ARTICLE; CHICKENPOX; CLINICAL STUDY; COST CONTROL; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; FETUS MORTALITY; GERMANY; HEALTH STATUS; HUMAN; INFANT; MATHEMATICAL MODEL; MEDICAL ASSESSMENT; MEDICAL INFORMATION; MEDICAL SOCIETY; MORBIDITY; PRESCHOOL CHILD; TREATMENT INDICATION; VACCINATION; VIRUS INFECTION;

CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; COST OF ILLNESS; COST SAVINGS; CROSS-SECTIONAL STUDIES; GERMANY; HUMANS; INFANT; MODELS, ECONOMIC; NATIONAL HEALTH PROGRAMS; VACCINATION;

EID: 33746242430     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-836610     Document Type: Article

References (45)

1. Banz K, Wagenpfeil S, Neiss A, Goertz A, Staginnus U, Vollmar J, Wutzler P. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 2003; 21: 1256-1267
2. Beutels P, Clara R, Tormans G, Van Doorslaer E, Van Damme P. Costs and benefits of routine varicella vaccination in German children. J Infect Dis 1996; 174 (Suppl 3): S335-S341
3. Boelle PY, Hanslik T. Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol Infect 2002; 129: 599-606
4. Bundesministerium für Gesundheit. Daten des Gesundheitswesens. Nomos Verlag, Baden-Baden 1999
5. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996; 45: 1-36
6. Centers for Disease Control and Prevention. National Immunization Survey Internet: www.cdc.gov/nip/coverage/default.htm 2002
7. Chant KG, Sullivan EA, Burgess MA, Ferson MJ, Forrest JM, Baird LM, Tudehope DI, Tilse M. Varicella-zoster infection in Australia. Aust NZ J Public Health 1998; 22: 413-418
8. Coudeville L, Paree F, Lebrun T, Sailly JC. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 1999; 17: 142-151
9. Gelbe Liste - Pharmindex. Internet: www.gelbe-liste.de/index.htm
10. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in health and medicine. Oxford University Press, New York 1996
11. Fairley CK, Miller E. Varicella-Zoster Virus Epidemiology - A changing scene? J Infect Dis 1996; 174 (Suppl 3): S314-S319
12. Gray GC, Palinkas LA, Kelley PW. Increasing incidence of varicella hospitalisations in United States army and navy personnel: are today's teenagers more susceptible? Should recruits be vaccinated? Pediatrics 1990; 86: 867-873
13. Guess HA, Broughton DD, Melton LJ, Kurland LT. Population-based studies of varicella complications. Pediatrics 1986; 78 (Suppl): 723-727
14. Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 1994; 140: 81-104
15. Halloran ME. Epidemiologic effects of varicella vaccination. Infect Dis Clin North Am 1996; 10: 631-655
16. Hammerschmidt T, Goertz A, Wagenpfeil S, Neiss A, Wutzler P, Banz K. Validation of health economic models: The example of EVITA. Value in Health 2003; 6: 551-559
17. IMS Health. Verschreibungsindex für Pharmazeutika VIP. IMS Health, Frankfurt/Main 2000
18. Institut der Deutschen Wirtschaft. Zahlen zur wirtschaftlichen Entwicklung der Bundesrepublik Deutschland 1999. Deutscher Instituts-Verlag GmbH, Köln 1999
19. Johnson CE, Stancin T, Fattlar D, Rome LP. A long-term prospective study of varicella vaccine in healthy children. Pediatrics 1997; 100: 761-767
20. Koopmanschap MA, Rutten F. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996; 10: 460-466
21. Kuter BJ, Weibel RE, Guess HA, Matthews H, Morton DH, Neff BJ, Provost PJ, Watson BA, Starr SE, Plotkin SA. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow up study. Vaccine 1991; 9: 643-647
22. Lieu TA, Cochi SL, Black SB, Halloran E, Shinefield HR, Holmes SJ, Wharton M, Washington E. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994; 271: 375-381
23. Manfredi R, Chiodo F, Titone L, Vierucci A, Catania S et al. Chickenpox complications among immunocompetent hospitalized children in Italy. Fed Med Chir 1997; 19: 99-104
24. Meyer PA, Seward JF, Jumaan AO. Varicella Mortality: Trends before Licensure in the United States (1970-1994). JID 2000; 182: 383-390
25. Preblud SR. Age-specific risks of varicella complications. Pediatrics 1981; 68: 14-17
26. Preblud SR, Orenstein WA, Koplan JP, Bart KJ, Hinman AR. A benefit-cost analysis of a childhood varicella vaccination programme. Postgraduate Medical Journal 1985; 61 (Suppl 4): 17-22
27. Rawson H, Crampin A, Noah N. Deaths from chickenpox in England and Wales 1995-7: analysis of routine mortality data. BMJ 2001; 323: 1091-1093
28. Sauerbrei A, Wutzler P. Varicella-Zoster Virusinfektion während der Schwangerschaft. Deutsches Ärzteblatt 1999; 96: A 1198-A 1203
29. Seward JF, Watson BM, Peterson CL, Mascola L et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002; 287: 606-611
30. Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, Wells ME, Stephenson WP, Gershon AA. The postmarketing safety profile of varicella vaccine. Vaccine 2001; 19: 916-923
31. Ständige Impfkommission. Impfempfehlungen der Ständigen Impfkommission (STIKO) am RKI/Stand: Juli 2001. Epidemiologisches Bulletin 2001; 28: 203-218
32. Ständige Impfkommission. Impfempfehlungen der Ständigen Impfkommission (STIKO) am RKI/Stand: Juli 2004. Epidemiologisches Bulletin 2004; 30: 235-250
33. Statistisches Bundesamt (Hrsg). Statistisches Jahrbuch für die Bundesrepublik Deutschland 2000. Verlag Metzler-Poeschel, Stuttgart 2000
34. Takahashi M. Current status and prospects of live attenuated vaccine. Vaccine 1992; 10: 1007-1014
35. Thiry N, Beutels P, Van Damme P, Van Doorslaer E. Economic evaluations of varicella vaccination programmes - A review of the literature. Pharmacoeconomics 2003; 21: 13-38
36. Tischer A, Geike E, Färber I, Sauerbrei A, Wutzler P. Seroprävalenz gegen Varicella-Zoster-Virus in Deutschland. Ergebnisse einer Studie des RKI und des Konsiliarlabors für HSV und VZV. Epidemiologisches Bulletin 2000; 46: 368-369
37. Varis T, Vesikari T. Efficacy of high-titer live attenuated varicella vaccine in healthy coung children. J Infect Dis 1996; 174 (Suppl 3): S330-S334
38. Verschreibungsindex für Pharmazeutika VIP. IMS 2000
39. Wagenpfeil S, Neiss A, Banz K, Wutzler P. Empirical data on the varizella situation in Germany for vaccination decisions. Clinical Microbiology and Infection 2004; 10: 425-430
40. Watson B. A review of varicella vaccine. Pediatr Ann 2001; 30: 362-367
41. Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ, Conor KA, McLean AA, Hillman MR, Buynak EB. Live attenuated varicella virus vaccine: efficacy trial in healthy children. N Engl J Med 1984; 310: 1409-1415
42. Wezel H, Liebhold R. Einheitlicher Bewertungsmaßstab für ärztliche Leistungen, 2000. Handkommentar BMA, E-GO und GOÄ. Asgard, St. Augustin 2000
43. Wutzler P, Neiss A, Banz K, Görtz A, Bisanz H. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood vaccination in Germany. Med Microbiol Immunol 2001; 191: 89-96
44. Wutzler P, Färber I, Wagenpfeil S, Bisanz H, Tischer A. Seroprevalence of varicella-zoster virus in the German population. Vaccine 2002; 20: 121-124
45. Ziebold C, Kries R von, Lang R, Weigl J, Schmitt HJ. Severe complications of varicella in previously healthy children in Germany: a 1-year survey. Pediatrics 2001; 108: 79-84